Biovis Diagnostik

What Biovis Diagnostik does

Biovis Diagnostik MVZ GmbH is a privately-held German medical diagnostic laboratory founded in 2005 and headquartered in Limburg-Eschhofen. The company provides approximately 1,000 laboratory analyses and tests spanning metabolomics, molecular genetics, clinical standard diagnostics, microbiology, immunology, and preventive medicine. Its proprietary platforms include the OmicSnap metabolome analysis, comprehensive microbiome analysis (250+ parameters via bacterial DNA sequencing from stool), Prevent 360 (75 parameters from 120 µl capillary blood), Mikrobolom 1.0 (microbial metabolic product analysis), and cytokine-release tests (K101 multi-pathogen, K611 mold/mycotoxin). The laboratory has held continuous DAkkS accreditation under DIN EN ISO 15189 since 2011 and successfully converted to the 2024 standard in 2025.

The company operates a pure B2B2C go-to-market model, serving physicians and therapists who order tests on behalf of patients via request forms, dedicated hotlines, and the Biovis Academy (seminars, webinars, congresses, and a Functional Medicine training program). Distribution is European in scope, with localized websites in German, English, Dutch, Italian, and Polish covering Germany, the Netherlands, Italy, Poland, Switzerland, and Austria. Revenue is generated through professional services — laboratory diagnostic testing with scientifically-derived individualized therapeutic recommendations — though no pricing or contract terms are publicly disclosed. Leadership is anchored by Scientific Director Prof. Dr. med. Burkhard Schütz, Medical Director Dr. med. Susanne Franck, and operational leads including Thomas Zielinski and Andrea Raddatz-Börsch.

Name

Biovis Diagnostik

Legal name

biovis Diagnostik MVZ GmbH

Website

https://biovis.eu

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

251–500 employees

Short description

Biovis Diagnostik is a German medical laboratory providing approximately 1,000 diagnostic tests spanning metabolomics, microbiome analysis, immunology, and preventive medicine, serving physicians and therapists across Europe via a B2B2C model with localized multi-language operations.

Ownership category

akta.pro rank

Product category

Clinical Laboratory Diagnostics

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Clinical Chemistry & Immunoassay Laboratories (HLAFAMAB)

akta.pro secondary industries

Biomarker Discovery & Validation (omics, assay feasibility, clinical validation) (HLAAAMAA), Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)

Keywords

• Clinical laboratory diagnostics
• Microbiome analysis
• Metabolomics testing
• Cytokine release testing
• Preventive medicine diagnostics

Headquarters

HQ city

Limburg

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Laboratory Diagnostic Services: Biovis Diagnostik generates revenue through providing laboratory diagnostic testing services to physicians and therapists. Healthcare professionals order specific tests (e.g., microbiome analysis, metabolomics, hormone panels) via request forms, and the laboratory processes samples and returns findings. Beyond pure lab diagnostics, services include scientifically-derived therapeutic recommendations individualized to each patient based on findings.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Core offering

Biovis Diagnostik is a German medical diagnostic laboratory that processes human samples (stool, capillary blood, serum, etc.) on behalf of physicians and therapists across Europe. It offers approximately 1,000 analyses spanning metabolomics, molecular genetics, clinical standard diagnostics, microbiology, and immunology, with proprietary platforms for microbiome analysis (Mikrobiomanalyse, Mikrobolom 1.0), capillary blood profiling (Prevent 360), metabolome profiling (OmicSnap), and cytokine release testing (K101, K611), returning lab findings together with scientifically-derived therapeutic recommendations.

Differentiator

Problem solved

Functional benefit

Products and services

• Microbiome Analysis (Mikrobiomanalyse) Complete stool-based microbiome diagnostic service for physicians and therapists, sequencing bacterial DNA from patient stool samples to assess gut flora composition, bacterial diversity, enterotype, and implications for vitamin/mineral absorption.
• Mikrobolom 1.0 Stool diagnostic service focused on microbial metabolic products rather than bacterial detection, allowing practitioners to evaluate active metabolic processes in the gut and their health implications for patients.
• Prevent 360 Minimally invasive capillary blood diagnostic service that determines 75 different health parameters from a 120 µl capillary blood sample, designed for comprehensive health screening in practitioner settings.
• Multierreger-Test (K101) Cytokine release test for multi-pathogen detection, providing functional immunological assessment for practitioners investigating chronic infections, persistent symptoms, or unclear immunological findings in patients.
• Schimmelpilzbelastungen (K611) Cytokine release test for detecting immunological reactions to mold and mycotoxin exposure, providing functional diagnostics for practitioners treating patients with suspected mold-related illness.
• OmicSnap Metabolome Analysis Metabolome profiling diagnostic service offering comprehensive metabolic assessment for physicians and therapists seeking detailed insight into patient metabolic status.
• Laboratory Diagnostic Service (Comprehensive) Core laboratory service through which physicians and therapists order tests via request forms, the laboratory processes patient samples, and returns findings together with scientifically-derived individualized therapeutic recommendations for integration into patient treatment concepts.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• Science-Tech GmbHminorOthersScience-Tech GmbH (Höllriegelskreuther Weg 3, 82065 Baierbrunn, Germany, Tel.: +49 89 – 2153 8122) provides technical operations and website maintenance services for biovis Diagnostik.

Scale indicators5 records

Recent moves1 record

Expansion highlights2 records

Direct peers

• Genova Diagnostics: US-based specialty diagnostic laboratory known for comprehensive stool, microbiome, and metabolomic profiles marketed to integrative and functional medicine practitioners. Genova is the international archetype that Biovis's Mikrobiomanalyse and OmicSnap offerings most closely resemble.
• LADR Laborverbund Deutscher Ärzte: Federation of German medical laboratories providing a broad clinical and specialty diagnostics menu to physicians. LADR represents the regional specialty/clinical lab peer competing with Biovis for physician referrals in the German market, though with a more conventional clinical emphasis.
• IMD Institut für Medizinische Diagnostik: Berlin-based specialty medical laboratory focused on metabolic, immunological, and environmental diagnostics, serving physicians and therapists. IMD overlaps directly with Biovis in specialty lab services for integrative and complementary medicine practitioners in Germany.
• Ganzimmun Diagnostics: Mainz-based German specialty medical laboratory with a comparable functional/preventive medicine focus, offering stool diagnostics, microbiome analysis, metabolomics, and immunology panels ordered by physicians and therapists. Ganzimmun is the closest direct competitor to Biovis in German functional laboratory diagnostics.

Broad incumbents

• Synlab: Europe's largest medical diagnostics services provider operating routine and specialty clinical labs across more than 30 countries. Synlab is a broad incumbent that could expand its specialty/functional offering to compete with Biovis in microbiome and metabolomic testing.
• Eurofins Scientific: Global bioanalytical testing group with significant clinical diagnostics and microbiome testing capabilities across Europe. Eurofins's clinical and specialty testing services are a broad alternative to Biovis, particularly for larger hospital and research customers.
• Medicover: Sweden-headquartered healthcare and diagnostics services group with significant operations in Germany, Poland, Romania, and other European countries. Medicover competes with Biovis in serving physicians in Germany and Poland with clinical and specialty lab services.
• Sonic Healthcare: Global medical diagnostics provider with a strong European footprint (Germany, Switzerland, Belgium, UK) operating routine and specialty laboratories. Sonic Healthcare's European subsidiaries compete for the same physician referral base as Biovis.

Regional players

• MVZ Labor Limbach: German medical laboratory network offering clinical chemistry, microbiology, and specialty diagnostics to physicians and hospitals. Located in a neighboring German region to Biovis, Labor Limbach represents a regional specialty lab peer in the same clinical market.

Emerging players

• Cerascreen: Hamburg-based consumer health diagnostics company offering microbiome, food intolerance, and hormone test kits direct to consumers and via partners. Cerascreen represents a direct-to-consumer emerging alternative to Biovis's B2B2C model in the same functional/preventive category.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/1943210656002254

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biovis Diagnostik